Literature DB >> 35280700

Mislocalization of Cancer-associated Thyroid Hormone Receptor Mutants.

Michael S Salomon1, S Harshini Malapati1, Jerry O' Dwyer1, Carolina Lopez Silva1, Cheyenne C Williams1, Michelle C Barbeau1, Delbert Yip1, Paige Punzalan1, Veronica L Nagle1, Shantá D Hinton1, Vincent R Roggero1, Lizabeth A Allison1.   

Abstract

The thyroid hormone receptor (TR) is essential for the proper regulation of metabolism and development, as it regulates gene expression in response to thyroid hormone. Nuclear localization signals (NLSs) and nuclear export signals (NESs) allow for TR transport into and out of the nucleus, respectively. Previous research suggests that nuclear import, nuclear retention, and nuclear export of TR are associated with modulation of gene expression, the alteration of which can contribute to various diseases. Here, we examined the impact of cancer-associated mutations on TR localization patterns as a way of analyzing key structural components of TR and to further explore the correlation between TR trafficking, misfolding, and disease. Through mammalian cell transfection of expression plasmids for green fluorescent protein (GFP) and mCherry-tagged TRα1 and quantitative fluorescence microscopy, we examined particular groups of TRα1 mutations that were observed in patients with hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer, and are associated with NLSs and NESs of TRα1. We also investigated structural alterations of the mutants by in silico modeling. Our results show striking shifts towards a more cytoplasmic localization for many of the mutants and an increased tendency to form cytosolic and nuclear aggregates.

Entities:  

Keywords:  Thyroid hormone receptor α; aggresome; cancer; nuclear export; nuclear import

Year:  2020        PMID: 35280700      PMCID: PMC8909557     

Source DB:  PubMed          Journal:  Nucl Receptor Res        ISSN: 2314-5706


  55 in total

Review 1.  Thyroid hormone receptors and cancer.

Authors:  Won Gu Kim; Sheue-yann Cheng
Journal:  Biochim Biophys Acta       Date:  2012-04-06

2.  Variable RXR requirements for thyroid hormone responsiveness of endogenous genes.

Authors:  Ericka M Diallo; Kenneth G Wilhelm; Deborah L Thompson; Ronald J Koenig
Journal:  Mol Cell Endocrinol       Date:  2006-12-11       Impact factor: 4.102

3.  Functionally impaired TR mutants are present in thyroid papillary cancer.

Authors:  Monika Puzianowska-Kuznicka; Agnieszka Krystyniak; Agnieszka Madej; Sheue-Yann Cheng; Janusz Nauman
Journal:  J Clin Endocrinol Metab       Date:  2002-03       Impact factor: 5.958

Review 4.  Chemistry and Biology in the Biosynthesis and Action of Thyroid Hormones.

Authors:  Santanu Mondal; Karuppusamy Raja; Ulrich Schweizer; Govindasamy Mugesh
Journal:  Angew Chem Int Ed Engl       Date:  2016-05-25       Impact factor: 15.336

5.  Cancer promoted by the oncoprotein v-ErbA may be due to subcellular mislocalization of nuclear receptors.

Authors:  Ghislain M C Bonamy; Anne Guiochon-Mantel; Lizabeth A Allison
Journal:  Mol Endocrinol       Date:  2005-01-13

Review 6.  Strategies for the inhibition of protein aggregation in human diseases.

Authors:  Manuela Bartolini; Vincenza Andrisano
Journal:  Chembiochem       Date:  2010-05-17       Impact factor: 3.164

7.  Multiple novel signals mediate thyroid hormone receptor nuclear import and export.

Authors:  Manohara S Mavinakere; Jeremy M Powers; Kelly S Subramanian; Vincent R Roggero; Lizabeth A Allison
Journal:  J Biol Chem       Date:  2012-07-19       Impact factor: 5.157

8.  Thyroid hormone receptor mutations in cancer and resistance to thyroid hormone: perspective and prognosis.

Authors:  Meghan D Rosen; Martin L Privalsky
Journal:  J Thyroid Res       Date:  2011-06-08

9.  The aggregation of mutant p53 produces prion-like properties in cancer.

Authors:  Luciana P Rangel; Danielly C F Costa; Tuane C R G Vieira; Jerson L Silva
Journal:  Prion       Date:  2014 Jan-Feb       Impact factor: 3.931

Review 10.  Futures Challenges in Thyroid Hormone Signaling Research.

Authors:  Frédéric Flamant
Journal:  Front Endocrinol (Lausanne)       Date:  2016-06-22       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.